Prevalence of programmed cell death ligand 1 (PD-L1) Expression among Tumor Samples from Iraqi Patients with Non-Small Cell Lung Cancer

Alaa Qasim Yahya, Zina A Rajab Alhamadani, Samir Z. Ahmed, Ahmad Fawzi Hussain

Abstract


Background: In a subgroup of patients with advanced stage lung cancer, immunotherapy that specifically targets the PD-L1/PD-1 pathway has been demonstrated to enhance survival. Expression of PD-L1 in cancer cells has been recognized as a promising biomarker for predicting the probable response of patients to anti-PD-L1 or anti-PD-1 therapy. The objective of this study is to examine the frequency of PD-L1 expression in non-small cell lung cancer (NSCLC) in Iraqi patients and its association with clinicopathological parameters that can offer useful insights for making treatment approaches more effective and enhancing clinical outcomes.

Methods: This is a cross sectional study on 94 non-small cell lung cancer tumor samples collected from teaching laboratories of Medical City Teaching Complex. The programmed cell death ligand 1 (PD-L1) expression was evaluated using immunohistochemistry. PD-L1 protein expression level is established by usage of Tumor Proportion Score (TPS). The specimen would be regarded to possess positive PD-L1expression result if the TPS ≥ 1% and to have high PD-L1 expression if the TPS ≥ 50%. PD-L1 expression is then compared with different clincopathological features.

Results: Positive PD-L1 expression (≥1%) was seen in 39 cases (41.5%) of NSCLC patients. In 12 cases (12.7%), there was high expression in ≥50% of tumor cells. of NSCLCs. A non-significant association was found between age& PD-L1 scores. While PD-L1 levels were significantly expressed with higher levels in female patients than males.

Conclusions: High levels of PD-L1 expression is observed in a significant percentage of NSCLC. Immunohistochemistry is needed to reveal cases that benefit from immunotherapy. A lower patient age was correlated with higher PD-L1 expression.

Keywords: Programmed cell death ligand 1, Non-Small Cell Lung Cancer, Tumor proportion score


Full Text:

PDF

References


Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clinics in chest medicine, (2011); 32(4):605-644.

Hussain A, Lafta R. Cancer trends in Iraq 2000–2016. Oman medical journal, (2021); 36(1):e219.

Kanitkar A, Schwartz A, George J, Soubani A. Causes of death in long-term survivors of non-small cell lung cancer: A regional Surveillance, Epidemiology, and End Results study. Annals of thoracic medicine, (2018); 13(2): 76-81.

Glatzel-Plucinska N, Piotrowska A, Grzegrzolka J, Olbromski M, Rzechonek A, Dziegiel P, Podhorska-Okolow M. SATB1 level correlates with Ki-67 expression and is a positive prognostic factor in non-small cell lung carcinoma. Anticancer Research, (2018); 38(2):723-736.

Lin G, Fan X, Zhu W, Huang C, Zhuang W et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget, (2017); 8(48): 83986-83994.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine, (2012); 366(26):2443-2454.

Brahmer J, Reckamp K, Baas P, Crinò L, Eberhardt W et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New England Journal of Medicine, (2015); 373(2):123-135.

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. New England Journal of Medicine, (2015); 373(17):1627-1639.

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A et al. Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine, (2015); 372(21):2018-2028.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine, (2012); 366(26):2455-2465.

Freeman G, Long A, Iwai Y, Bourque K, Chernova T et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of experimental medicine, (2000); 192(7):1027-1034.

Dong H, Strome S, Salomao D, Tamura H, Hirano F et al. Tumour-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine, (2002); 8(8):793-800.

Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature medicine, (1999); 5(12): 1365-1369.

Hamid O, Robert C, Daud A, Hodi F, Hwu W et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. New England Journal of Medicine, (2013); 369(2):134-144.

Scheel A, Schäfer S. Current PD-L1 immunohistochemistry for non-small cell lung cancer. Journal of thoracic disease, (2018); 10(3): 1217-1219.

Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Csőszi T et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New England Journal of Medicine, (2016); 375(19):1823-1833.

Technologies A. PD-L1 IHC 22C3 pharmDx Interpretation Manual – Non-small Cell Lung Cancer (NSCLC). Agilent Technologies Manuals, (2020);1:1-8818.

Al-Rahim Y. Lung Cancer in a sample of Iraqi patients. Al-Kindy College Medical Journal, (2007); 4(1):53-61

Al-Rahim Y. Lung Cancer in a sample of Iraqi patients. Al-Kindy College Medical Journal, (2007); 4(1):53-61.

Al-Khateeb Z, Mahdi L. Prevalence of Lung Cancer in Al Najaf Governorate Registered in Middle Euphrates Oncology Center during 2019 and 2020. Journal of the Faculty of Medicine Baghdad, (2022); 64(1):22-30.

Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological

factors and diagnostic markers. International journal of molecular sciences, (2019); 20(4):824.

Gelatti A, Cordeiro de Lima V, Freitas H, Werutsky G, Gaiger A et al. Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer, (2020); 21(6): e511–e515.

Tolwin Y, Gillis R, Peled N. Gender and lung cancer—SEER-based analysis. Annals of Epidemiology, (2020); 46:14-19.

Guarga L, Ameijide A, Marcos-Gragera R, Carulla M, Delgadillo J et al. Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Scientific Reports, (2021); 11(1):23274.

Zhang X, Wu L, Xu Y, Zhang B, Wu X et al. Trends in the incidence rate of lung cancer by histological type and gender in Sichuan, China, 1995–2015: A single‐center retrospective study. Thoracic Cancer, (2018); 9(5):532-541.

Tsunoda A, Morikawa K, Inoue T, Miyazawa T, Hoshikawa M et al. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. BMC cancer, (2019); 19:1-8.

Dietel M, Savelov N, Salanova R, Micke P, Bigras G et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer, (2019); 134:174-179.

Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer biology & medicine, (2016); 13(2):157.

Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clinical cancer research, (2004); 10(15):5094-5100.

Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Medical oncology, (2011); 28:682-688.

Cooper W, Tran T, Vilain R, Madore J, Selinger C et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, (2015); 89(2):181-188.

Kim MY, Koh J, Kim S, Go H, Jeon YK et al. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer, (2015); 88(1):24-33.

Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Yang. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. European journal of cancer, (2014); 50(7):1361-1369.




DOI: http://dx.doi.org/10.62940/als.v12i1.3201

Refbacks

  • There are currently no refbacks.